9/4/2020 8:04:19 AM
Lexicon Pharma Begins Patient Dosing In RELIEF-DPN-1 Phase 2 Clinical Study Of LX9211
8/3/2020 7:26:37 AM
TerSera Therapeutics Enters Definitive Agreement To Acquire Product Xermelo From Lexicon
7/21/2020 7:09:23 AM
Lexicon: All Four Phase 3 Sotagliflozin Studies Met Primary Objectives Of Lowering A1C In Patients With Type 2 Diabetes
4/27/2020 7:19:21 AM
Lexicon Q1 Revenues Decrease To $8.0 Mln From $9.2 Mln Last Year
3/12/2020 7:23:19 AM
Lexicon Q4 Loss $51.1 Mln Or $0.48/Shr Vs Loss $16.8 Mln Or $0.16/Shr Year-ago
12/20/2019 7:07:28 AM
Lexicon Pharma Topline Phase 3 Data For Sotagliflozin In Type 2 Diabetes Meets End Points
12/5/2019 7:14:16 AM
Lexicon Announces Positive Topline Data From Phase 1 Study Of LX9211
12/2/2019 7:21:58 AM
Lexicon Pharma Gets Formal Dispute Resolution Request Decision From FDA’s Office Of New Drugs For Sotagliflozin
9/10/2019 4:06:28 PM
Lexicon Pharmaceuticals Announces Termination Of Alliance And Settlement With Sanofi
8/1/2019 10:10:16 AM
Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $17 Down From $35 Price Target